Is this U.S.-China selloff a buy? A top Wall Street voice weighs in
Investing.com - Citizens raised its price target on Aquestive Therapeutics (NASDAQ:AQST) to $12.00 from $9.00 while maintaining a Market Outperform rating. The stock, currently trading at $6.20, has seen remarkable momentum with a 140% surge over the past six months. According to InvestingPro data, analyst targets for AQST range from $4.75 to $15.00, with a strong buy consensus.
The price target increase follows Aquestive’s announcement of two additional patents for Anaphylm, which extend the brand’s exclusivity through at least 2037.
Citizens views these patents as "meaningfully value accretive" since they cover compositions of matter for the novel epinephrine prodrug used in the product candidate.
The firm updated its financial model to project sales through year-end 2037, compared to its previous projection through 2034, which directly contributed to the higher price target.
The research firm’s sum-of-the-parts derived price target reflects increased confidence in Anaphylm’s extended exclusivity period.
In other recent news, Aquestive Therapeutics has received two new patents for its Anaphylm dibutepinephrine sublingual film, which will extend protection until at least 2037. The film is an oral alternative to injectable epinephrine for treating severe allergic reactions. Additionally, the U.S. Food and Drug Administration has decided not to require an advisory committee meeting for Anaphylm, keeping the company on track for a regulatory decision by January 31, 2026. Aquestive has also secured a $75 million strategic funding agreement with RTW Investments, contingent on FDA approval of Anaphylm, to support commercialization efforts through 2027. Piper Sandler and Cantor Fitzgerald both reiterated their Overweight ratings on Aquestive stock, with price targets of $5.00 and $15.00, respectively. Piper Sandler’s survey of allergists indicated significant interest in Anaphylm’s non-injectable delivery method. Cantor Fitzgerald highlighted the potential market shift toward needle-less epinephrine administration as a significant opportunity for Aquestive. These developments suggest growing support and interest in Aquestive’s innovative product offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.